Cinclus Pharma (CINPHA) — Working Capital to Net Assets Ratio
Cinclus Pharma (CINPHA) has a Working Capital to Net Assets ratio of 116.2% as of June 2026. Working capital of Skr235.55 Million (current assets of Skr416.56 Million minus current liabilities of Skr181.02 Million) is measured against net assets of Skr202.70 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See operational self-sufficiency of Cinclus Pharma to measure how many days the company can operate on defensive assets alone.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Cinclus Pharma Working Capital to Net Assets (2022–2025)
This chart shows how Cinclus Pharma's Working Capital to Net Assets ratio has evolved across 4 annual periods from 2022 to 2025. As of June 2026, the ratio stands at 116.2%, reflecting working capital of Skr235.55 Million against net assets of Skr202.70 Million SEK. For the complete balance sheet picture, see CINPHA total asset value.
Annual Working Capital to Net Assets for Cinclus Pharma (2022–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Cinclus Pharma from 2022 to 2025, covering 4 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. Read CINPHA total debt and obligations for a breakdown of total debt and financial obligations.
| Year | WC/NA Ratio | Working Capital (SEK) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 108.3% | Skr400.06 Million | Skr369.39 Million | Skr536.85 Million | Skr136.79 Million | ▲ +8.4 pp |
| 2024 | 99.9% | Skr554.97 Million | Skr555.33 Million | Skr600.47 Million | Skr45.49 Million | ▲ +8.4 pp |
| 2023 | 91.6% | Skr-70.33 Million | Skr-76.80 Million | Skr94.09 Million | Skr164.42 Million | ▼ -17.8 pp |
| 2022 | 109.4% | Skr138.78 Million | Skr126.87 Million | Skr184.88 Million | Skr46.10 Million | — |